Top Two CMV Driver Mortality Causes: 2026 Guidelines and Prevention (Part 1 of 2)

The American College of Cardiology, American Heart Association and nine other major medical associations issued updated guidelines for managing cardiovascular risk. In our two-part series, this episode examined the leading causes of commercial motor vehicle (CMV) driver mortality, key biomarkers for assessing risk and the latest clinical therapies. Join us on June 10 for part two, which focuses on lifestyle levers to optimize these health markers, specifically VO2 max. This is part of the North American Fatigue Management Program’s (NAFMP) ongoing series on commercial driver fatigue.

CHAPTERS

00:00:00 — Introduction & Agenda Overview
Welcome, speaker introductions, agenda breakdown, and a reminder for Part 2 of the series.

00:03:51 — Why Focus on CMV Driver Health?
The fiduciary duty of drivers and carriers to ensure long-term viability, health as a professional asset, and an important medical disclaimer.

00:09:19 — The #1 Biological Cause of Death: ASCVD
A deep dive into Atherosclerotic Cardiovascular Disease, plaque formation, heart attack mechanics, and driver life expectancy statistics.

00:17:46 — The #1 Occupational Hazard: Fatigue
How fatigue-related crashes serve as the top occupational hazard and how exhaustion physically compounds cardiovascular risk.

00:23:28 — Assessing Risk: Biomarkers & The PREVENT Calculator
Understanding critical biomarkers, the transition to the new PREVENT online calculator, and measuring baseline risks.

00:28:37 — 2026 Guidelines: Early Intervention & Risk Categorization
An overview of the March 2026 guideline updates, the shift toward primary prevention, and aggressive early intervention strategies.

00:35:27 — Advanced Risk Assessment: ApoB, Lp(a), and CAC Scores
Looking beyond standard lipid panels to measure ApoB, genetic Lp(a) factors, and Coronary Artery Calcium (CAC) scores.

00:48:55 — Clinical Therapies: From Statins to Gene Therapy
A review of medical treatments to manage cholesterol, including statins, ezetimibe, PCSK9 inhibitors, RNAi, and futuristic gene therapies.

00:53:07 — Integrating Health into Safety Culture & NAFMP Resources
How to modify risky behaviors through organizational culture, driver education, and utilizing free NAFMP modules and tools.

00:55:54 — Audience Q&A Session
Addressing live and pre-submitted questions on biometric monitoring, leadership buy-in, health bonuses, FMCSA physicals, scheduling, and sleep apnea.